GlassScriptPhysician profile
Laura Spyche
NPI 1760511034
$24,407.30
in general payments reported to CMS, 2019-2025
25 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9,012 · 2022: $8,932 · 2023: $1,101 · 2024: $5,237 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,500 · Food and Beverage: $1,689 · Travel and Lodging: $210 · Education: $64.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,500.00 |
| Food and Beverage | $1,688.81 |
| Travel and Lodging | $210.38 |
| Education | $64.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $21,596.16 | 2021-2024 | Velphoro |
| Astrazeneca Pharmaceuticals LP | $780.14 | 2021-2024 | Farxiga, Breztri, Lokelma |
| Lilly USA, LLC | $418.75 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $333.73 | 2021-2024 | Parsabiv, Aranesp, Otezla |
| Travere Therapeutics, INC. | $155.85 | 2023-2024 | |
| Novo Nordisk INC | $153.73 | 2021-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $127.78 | 2021-2023 | |
| Acadia Pharmaceuticals INC | $124.99 | 2025 | Nuplazid |
| Glaxosmithkline, LLC. | $110.67 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Vifor Pharma, INC. | $102.55 | 2021-2023 | Veltassa |
| Akebia Therapeutics INC | $87.35 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.89 | 2021-2024 | |
| Exact Sciences Corporation | $45.33 | 2023 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $42.66 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.08 | 2022-2023 | Gattex |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vbi Vaccine (Delaware) INC. | $29.64 | 2022-2023 | Prehevbrio |
| Phathom Pharmaceuticals, INC. | $29.14 | 2024 | Voquezna |
| Dexcom, INC. | $28.62 | 2021-2023 | Dexcom G6 Transmitter |
| Ardelyx, INC. | $21.17 | 2023 | Ibsrela |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.89 | 2022 | |
| Opko Pharmaceuticals, LLC | $20.26 | 2023 | Rayaldee |
| Kyowa Kirin, INC. | $19.19 | 2024 | Crysvita |
| Abbott Laboratories | $14.99 | 2022 | |
| Aurinia Pharma U.S., INC. | $14.45 | 2021 | |
| Daiichi Sankyo INC. | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Spyche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.